Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.

Autor: Bennett C; Novavax, Gaithersburg, MD, USA. Electronic address: cbennett@novavax.com., Woo W; Novavax, Gaithersburg, MD, USA., Bloch M; Holdsworth House Medical Practice, Sydney, NSW, Australia; Kirby Institute, University of New South Wales, Sydney, NSW, Australia., Cheung K; Emeritus Research, Camberwell, VIC, Australia., Griffin P; Mater Health, Mater Medical Centre, South Brisbane, QLD, Australia; The University of Queensland, Mater Clinical Unit, Brisbane St Lucia, QLD, Australia., Mohan R; Paratus Clinical Research Western Sydney, Blacktown, NSW, Australia., Deshmukh S; Griffith University, Southport, QLD, Australia., Arya M; Australian Clinical Research Network, Maroubra, NSW, Australia., Cumming O; Novatrials, Kotara, NSW, Australia., Neville AM; AusTrials, Taringa, QLD, Australia., McCallum Pardey TG; Novatrials, Kotara, NSW, Australia., Plested JS; Novavax, Gaithersburg, MD, USA., Cloney-Clark S; Novavax, Gaithersburg, MD, USA., Zhu M; Novavax, Gaithersburg, MD, USA., Kalkeri R; Novavax, Gaithersburg, MD, USA., Patel N; Novavax, Gaithersburg, MD, USA., Marcheschi A; Novavax, Gaithersburg, MD, USA., Swan J; Novavax, Gaithersburg, MD, USA., Smith G; Novavax, Gaithersburg, MD, USA., Cho I; Novavax, Gaithersburg, MD, USA., Glenn GM; Novavax, Gaithersburg, MD, USA., Walker R; Novavax, Gaithersburg, MD, USA., Mallory RM; Novavax, Gaithersburg, MD, USA.

Publikováno v: The Lancet. Infectious diseases [Lancet Infect Dis] 2024 Jun; Vol. 24 (6), pp. 581-593. Date of Electronic Publication: 2024 Mar 06.